Core Viewpoint - Akanda Corp. has announced a $12.0 million convertible note offering to institutional investors, which will be utilized for various corporate purposes [1][2]. Group 1: Financial Details - The offering consists of 12-month convertible promissory notes with an aggregate purchase price of up to $12.0 million [1]. - Proceeds from the sale will be allocated as follows: up to $3.5 million for marketing, continued development of the Gabriola, B.C. site, up to $3 million for working capital and general corporate purposes, and up to $7 million for debt repayment [2]. Group 2: Transaction Agents - Univest Securities, LLC served as the exclusive placement agent for the offering [3]. - Legal counsel for the transaction included Ruskin Moscou Faltischek PC for the Company and Sullivan & Worcester LLP for the placement agent, with Gowling WLG (Canada) LLP acting as Canadian counsel [3]. Group 3: Regulatory Information - The notes and common shares from the conversion have not been registered under the Securities Act of 1933 and cannot be offered or sold in the U.S. without registration or an exemption [4]. - Additional details regarding the notes and the transaction will be available in the Company's Form 6-K, which will be filed with the U.S. Securities and Exchange Commission [5].

Core Points - Indaptus Therapeutics, Inc. has raised a total of $5.7 million through the sale of convertible promissory notes and accompanying warrants [1][2] - The notes have a 6% annual interest rate and will mature on July 28, 2026, with conversion into common stock at a price equal to 80% of the average Nasdaq closing price for the five trading days prior to conversion, capped at $11.20 [2] - Warrants to purchase 200% of the conversion shares will be issued upon conversion, with an exercise price equal to the conversion price and a term of five years [3] - The net proceeds from the offering will be used for research and development activities, including funding a Phase 1b/2 clinical trial, as well as for working capital and general corporate purposes [4]